Healthcare -
Biotechnology - NASDAQ - US
$ 0.2191
-3.44 %
$ 2.42 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart WINT
FINANCIALS
Balance Sheet
Windtree Therapeutics, Inc.
| Current Assets | 5.38 M |
| Cash & Short-Term Investments | 4.32 M |
| Receivables | 0 |
| Other Current Assets | 1.06 M |
| Non-Current Assets | 27 M |
| Long-Term Investments | 0 |
| PP&E | 1.63 M |
| Other Non-Current Assets | 25.4 M |
| Current Liabilities | 4 M |
| Accounts Payable | 809 K |
| Short-Term Debt | 669 K |
| Other Current Liabilities | 2.52 M |
| Non-Current Liabilities | 25 M |
| Long-Term Debt | 16.2 M |
| Other Non-Current Liabilities | 8.86 M |
EFFICIENCY
Earnings Waterfall
Windtree Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 82 K |
| Gross Profit | -82 K |
| Operating Expenses | 17.5 M |
| Operating Income | -17.5 M |
| Other Expenses | 2.75 M |
| Net Income | -20.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Windtree Therapeutics, Inc.
| Net Income | -20.3 M |
| Depreciation & Amortization | 82 K |
| Capital Expenditures | -15 K |
| Stock-Based Compensation | 1.28 M |
| Change in Working Capital | 2.02 M |
| Others | 4.93 M |
| Free Cash Flow | -13.5 M |
Wall Street Analysts Price Targets
Windtree Therapeutics, Inc.
WINT has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
WINT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Windtree Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
4.94 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 months ago
Oct 08, 2024
|
Bought
4.94 K USD
|
Fraser Craig
President and CEO
|
+ 5431
|
0.9099 USD |
|
1 year ago
Sep 27, 2023
|
Bought
2.55 K USD
|
Fraser Craig
President and CEO
|
+ 2500
|
1.0199 USD |
|
1 year ago
Sep 26, 2023
|
Bought
2.25 K USD
|
Fraser Craig
President and CEO
|
+ 2500
|
0.9 USD |
|
1 year ago
Apr 26, 2023
|
Bought
2.65 K USD
|
Fraser Craig
President and CEO
|
+ 1497
|
1.77 USD |
|
1 year ago
Apr 25, 2023
|
Bought
2.49 K USD
|
Fraser Craig
President and CEO
|
+ 1315
|
1.89 USD |
|
2 years ago
Jul 27, 2022
|
Bought
950 USD
|
Fraser Craig
President and CEO
|
+ 2500
|
0.3799 USD |
|
2 years ago
Jul 26, 2022
|
Bought
1.1 K USD
|
Hamill John P.
SVP & CFO
|
+ 3000
|
0.3666 USD |
|
2 years ago
Jul 26, 2022
|
Bought
935 USD
|
Fraser Craig
President and CEO
|
+ 2500
|
0.374 USD |
|
2 years ago
Jun 30, 2022
|
Bought
1.93 K USD
|
Fraser Craig
President and CEO
|
+ 4500
|
0.4279 USD |
|
2 years ago
Jun 29, 2022
|
Bought
2.91 K USD
|
Fraser Craig
President and CEO
|
+ 7000
|
0.4154 USD |
|
2 years ago
Mar 16, 2022
|
Bought
1.96 K USD
|
Fraser Craig
President and CEO
|
+ 2000
|
0.9799 USD |
|
2 years ago
Mar 15, 2022
|
Bought
5 K USD
|
Simonson Steven
SVP, Chief Medical Officer
|
+ 5000
|
0.9998 USD |
|
2 years ago
Mar 15, 2022
|
Bought
2.94 K USD
|
Fraser Craig
President and CEO
|
+ 3000
|
0.9801 USD |
|
4 years ago
May 20, 2020
|
Bought
400 K USD
|
Center Laboratories, Inc.
10 percent owner
|
+ 55172
|
7.25 USD |
|
3 years ago
Dec 30, 2021
|
Bought
1.98 M USD
|
Center Laboratories, Inc.
10 percent owner
|
+ 1239088
|
1.6 USD |
|
4 years ago
May 20, 2020
|
Bought
430 K USD
|
Center Laboratories, Inc.
10 percent owner
|
+ 55172
|
7.795 USD |
|
4 years ago
May 20, 2020
|
Bought
400 K USD
|
Bioengine Capital Inc.
10 percent owner
|
+ 55172
|
7.25 USD |
|
4 years ago
May 20, 2020
|
Bought
440 K USD
|
Bioengine Capital Inc.
10 percent owner
|
+ 55172
|
7.975 USD |
|
3 years ago
Dec 30, 2021
|
Sell 1.98 M
USD
|
Bioengine Capital Inc.
10 percent owner
|
- 1239088
|
1.6 USD |
|
3 years ago
Nov 19, 2021
|
Bought
1.49 K USD
|
Fraser Craig
President and CEO
|
+ 930
|
1.6 USD |
|
3 years ago
Nov 18, 2021
|
Bought
1.5 K USD
|
Fraser Craig
President and CEO
|
+ 930
|
1.61 USD |
|
3 years ago
Oct 22, 2021
|
Bought
5.7 K USD
|
Fraser Craig
President and CEO
|
+ 3000
|
1.9 USD |
|
3 years ago
Oct 19, 2021
|
Bought
95.1 K USD
|
Huang James
Director
|
+ 50000
|
1.9027 USD |
|
3 years ago
Oct 19, 2021
|
Bought
5.73 K USD
|
Fraser Craig
President and CEO
|
+ 3000
|
1.91 USD |
|
3 years ago
Apr 16, 2021
|
Bought
2.09 K USD
|
Fraser Craig
President and CEO
|
+ 1000
|
2.092 USD |
|
3 years ago
Apr 16, 2021
|
Bought
2.07 K USD
|
Hamill John P.
SVP & CFO
|
+ 1000
|
2.0669 USD |
|
3 years ago
Apr 15, 2021
|
Bought
2.24 K USD
|
Fraser Craig
President and CEO
|
+ 1000
|
2.2399 USD |
|
3 years ago
Apr 07, 2021
|
Bought
1.99 K USD
|
Curtis Eric
SVP & COO
|
+ 791
|
2.5172 USD |
|
3 years ago
Apr 06, 2021
|
Bought
1.28 K USD
|
Fraser Craig
President and CEO
|
+ 500
|
2.57 USD |
|
3 years ago
Apr 05, 2021
|
Bought
2.58 K USD
|
Fraser Craig
President and CEO
|
+ 1000
|
2.5799 USD |
|
3 years ago
Apr 01, 2021
|
Bought
1.23 K USD
|
Fraser Craig
President and CEO
|
+ 500
|
2.4587 USD |
|
3 years ago
Mar 31, 2021
|
Bought
354 K USD
|
Huang James
director, 10 percent owner:
|
+ 150000
|
2.36 USD |
|
3 years ago
Mar 31, 2021
|
Bought
1.16 K USD
|
Fraser Craig
President and CEO
|
+ 500
|
2.3199 USD |
|
3 years ago
Mar 25, 2021
|
Bought
4.88 K USD
|
Simonson Steven
SVP, Chief Medical Officer
|
+ 1500
|
3.25 USD |
|
3 years ago
Mar 25, 2021
|
Bought
5.4 K USD
|
Simonson Steven
SVP, Chief Medical Officer
|
+ 1500
|
3.6 USD |
|
3 years ago
Mar 25, 2021
|
Bought
4.88 K USD
|
Hamill John P.
SVP & CFO
|
+ 1500
|
3.25 USD |
|
3 years ago
Mar 25, 2021
|
Bought
5.4 K USD
|
Hamill John P.
SVP & CFO
|
+ 1500
|
3.6 USD |
|
3 years ago
Mar 25, 2021
|
Bought
4.88 K USD
|
Fraser Craig
President and CEO
|
+ 1500
|
3.25 USD |
|
3 years ago
Mar 25, 2021
|
Bought
5.4 K USD
|
Fraser Craig
President and CEO
|
+ 1500
|
3.6 USD |
|
4 years ago
Oct 28, 2020
|
Bought
1.64 K USD
|
Fraser Craig
President and CEO
|
+ 250
|
6.5595 USD |
|
4 years ago
Oct 23, 2020
|
Bought
6.67 K USD
|
Huang James
director, 10 percent owner:
|
+ 1000
|
6.666 USD |
|
4 years ago
Jun 04, 2020
|
Bought
87.9 K USD
|
Huang James
director, 10 percent owner:
|
+ 12000
|
7.3223 USD |
|
4 years ago
Oct 09, 2020
|
Bought
1.46 K USD
|
Fraser Craig
President and CEO
|
+ 250
|
5.825 USD |
|
4 years ago
Oct 07, 2020
|
Bought
5.27 K USD
|
Hamill John P.
SVP & CFO
|
+ 1000
|
5.27 USD |
|
4 years ago
Oct 07, 2020
|
Bought
1.29 K USD
|
Fraser Craig
President and CEO
|
+ 250
|
5.17 USD |
|
4 years ago
Oct 08, 2020
|
Bought
2.64 K USD
|
Curtis Eric
SVP & COO
|
+ 500
|
5.27 USD |
|
4 years ago
Jun 04, 2020
|
Bought
89.3 K USD
|
Huang James
director, 10 percent owner:
|
+ 12200
|
7.3223 USD |
|
4 years ago
Jun 03, 2020
|
Bought
1.48 K USD
|
Huang James
director, 10 percent owner:
|
+ 200
|
7.4199 USD |
|
4 years ago
May 22, 2020
|
Bought
8 K USD
|
Templeton Mary B Esq
SVP, Gen Counsel & Corp Sec
|
+ 1103
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
8.8 K USD
|
Templeton Mary B Esq
SVP, Gen Counsel & Corp Sec
|
+ 1103
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
3.26 K USD
|
Tattory John A
SVP & CFO
|
+ 449
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
3.58 K USD
|
Tattory John A
SVP & CFO
|
+ 449
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
3.75 K USD
|
Simonson Steven
SVP, Chief Medical Officer
|
+ 517
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
4.12 K USD
|
Simonson Steven
SVP, Chief Medical Officer
|
+ 517
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
15 K USD
|
Fraser Craig
President and CEO
|
+ 2069
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
16.5 K USD
|
Fraser Craig
President and CEO
|
+ 2069
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
15 K USD
|
Schreiber Brian D
Director
|
+ 2069
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
16.5 K USD
|
Schreiber Brian D
Director
|
+ 2069
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
25.4 K USD
|
PEACOCK BRUCE
Director
|
+ 3500
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
27.9 K USD
|
PEACOCK BRUCE
Director
|
+ 3500
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
15 K USD
|
Joseph Mahady M
Director
|
+ 2069
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
16.5 K USD
|
Joseph Mahady M
Director
|
+ 2069
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
15 K USD
|
Leone John R
Director
|
+ 2069
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
16.5 K USD
|
Leone John R
Director
|
+ 2069
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
2 M USD
|
Huang James
director, 10 percent owner:
|
+ 275862
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
2.2 M USD
|
Huang James
director, 10 percent owner:
|
+ 275862
|
7.975 USD |
|
4 years ago
May 22, 2020
|
Bought
15 K USD
|
Geffken Daniel E.
Director
|
+ 2069
|
7.25 USD |
|
4 years ago
May 22, 2020
|
Bought
16.5 K USD
|
Geffken Daniel E.
Director
|
+ 2069
|
7.975 USD |
|
4 years ago
Feb 18, 2020
|
Bought
1.54 K USD
|
Huang James
director, 10 percent owner:
|
+ 400
|
3.8375 USD |
|
4 years ago
Feb 11, 2020
|
Bought
1.02 K USD
|
Fraser Craig
President and CEO
|
+ 250
|
4.1 USD |
|
4 years ago
Feb 10, 2020
|
Bought
1.02 K USD
|
Fraser Craig
President and CEO
|
+ 250
|
4.1 USD |
|
4 years ago
Feb 07, 2020
|
Bought
2.02 K USD
|
Huang James
director, 10 percent owner:
|
+ 500
|
4.05 USD |
|
4 years ago
Feb 04, 2020
|
Bought
2.12 K USD
|
Fraser Craig
President and CEO
|
+ 500
|
4.24 USD |
|
4 years ago
Feb 03, 2020
|
Bought
420 USD
|
Fraser Craig
President and CEO
|
+ 100
|
4.2 USD |
|
5 years ago
Jan 17, 2020
|
Bought
8.37 K USD
|
Huang James
director, 10 percent owner:
|
+ 2000
|
4.1829 USD |
|
5 years ago
Jan 16, 2020
|
Bought
244 USD
|
Huang James
director, 10 percent owner:
|
+ 58
|
4.2 USD |
|
5 years ago
Dec 31, 2019
|
Bought
62.5 K USD
|
Huang James
director, 10 percent owner:
|
+ 15442
|
4.049 USD |
|
5 years ago
Dec 30, 2019
|
Bought
3.46 K USD
|
Huang James
director, 10 percent owner:
|
+ 909
|
3.81 USD |
|
5 years ago
Dec 27, 2019
|
Bought
15.3 K USD
|
Huang James
director, 10 percent owner:
|
+ 4091
|
3.7303 USD |
|
5 years ago
Dec 06, 2019
|
Bought
5 M USD
|
LPH II Investments Ltd
10 percent owner
|
+ 1655629
|
3.02 USD |
|
5 years ago
Dec 06, 2019
|
Bought
3.34 M USD
|
LPH II Investments Ltd
10 percent owner
|
+ 827815
|
4.03 USD |
|
5 years ago
Dec 06, 2019
|
Bought
5 M USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 1655629
|
3.02 USD |
|
5 years ago
Dec 06, 2019
|
Bought
3.34 M USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 827815
|
4.03 USD |
|
5 years ago
Dec 06, 2019
|
Bought
5 M USD
|
Huang James
director, 10 percent owner:
|
+ 1655629
|
3.02 USD |
|
5 years ago
Dec 06, 2019
|
Bought
3.34 M USD
|
Huang James
director, 10 percent owner:
|
+ 827815
|
4.03 USD |
|
6 years ago
Dec 21, 2018
|
Bought
5.99 M USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 1810938
|
3.31 USD |
|
6 years ago
Dec 21, 2018
|
Bought
33.5 M USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 8063861
|
4.15 USD |
|
6 years ago
Dec 21, 2018
|
Bought
2.42 M USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 597610
|
4.05 USD |
|
6 years ago
Dec 21, 2018
|
Bought
1.13 M USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 307859
|
3.68 USD |
|
6 years ago
Dec 21, 2018
|
Bought
5.99 M USD
|
LPH II Investments Ltd
10 percent owner
|
+ 1810938
|
3.31 USD |
|
6 years ago
Dec 21, 2018
|
Bought
1.13 M USD
|
LPH II Investments Ltd
10 percent owner
|
+ 307859
|
3.68 USD |
|
6 years ago
Dec 21, 2018
|
Bought
2.42 M USD
|
LPH II Investments Ltd
10 percent owner
|
+ 597610
|
4.05 USD |
|
6 years ago
Apr 04, 2018
|
Bought
2.6 M USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 541667
|
4.8 USD |
|
6 years ago
Apr 04, 2018
|
Bought
748 K USD
|
Lee's Pharmaceutical Holdings Ltd
10 percent owner
|
+ 135417
|
5.52 USD |
|
7 years ago
Feb 13, 2017
|
Bought
23.3 K USD
|
PEACOCK BRUCE
Director
|
+ 17000
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
23.3 USD
|
PEACOCK BRUCE
Director
|
+ 17
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
23.3 K USD
|
Joseph Mahady M
Director
|
+ 17000
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
23.3 USD
|
Joseph Mahady M
Director
|
+ 17
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
17.8 K USD
|
Leone John R
Director
|
+ 13000
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
17.8 USD
|
Leone John R
Director
|
+ 13
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
4.11 K USD
|
Simonson Steven
SVP, Chief Development Officer
|
+ 3000
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
4.11 USD
|
Simonson Steven
SVP, Chief Development Officer
|
+ 3
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
9.59 K USD
|
Fraser Craig
President and CEO
|
+ 7000
|
1.37 USD |
|
7 years ago
Feb 13, 2017
|
Bought
9.59 USD
|
Fraser Craig
President and CEO
|
+ 7
|
1.37 USD |
|
8 years ago
Oct 28, 2016
|
Bought
15.4 K USD
|
Fraser Craig
President and CEO
|
+ 7500
|
2.0508 USD |
|
9 years ago
Jul 22, 2015
|
Bought
30 K USD
|
Leone John R
Director
|
+ 50000
|
0.6 USD |
|
9 years ago
Jul 22, 2015
|
Bought
35 K USD
|
Leone John R
Director
|
+ 50000
|
0.7 USD |
|
9 years ago
Jul 22, 2015
|
Bought
10 K USD
|
Templeton Mary B Esq
SVP, Gen Counsel & Corp Sec
|
+ 16667
|
0.6 USD |
|
9 years ago
Jul 22, 2015
|
Bought
11.7 K USD
|
Templeton Mary B Esq
SVP, Gen Counsel & Corp Sec
|
+ 16667
|
0.7 USD |
|
9 years ago
Jul 22, 2015
|
Bought
5 K USD
|
Tattory John A
SVP & Chief Financial Officer
|
+ 8333
|
0.6 USD |
|
9 years ago
Jul 22, 2015
|
Bought
5.83 K USD
|
Tattory John A
SVP & Chief Financial Officer
|
+ 8333
|
0.7 USD |
|
9 years ago
Jul 22, 2015
|
Bought
10 K USD
|
Simonson Steven
SVP, Chief Development Officer
|
+ 16667
|
0.6 USD |
|
9 years ago
Jul 22, 2015
|
Bought
11.7 K USD
|
Simonson Steven
SVP, Chief Development Officer
|
+ 16667
|
0.7 USD |
|
9 years ago
Jul 22, 2015
|
Bought
25 K USD
|
COOPER JOHN G
President & CEO
|
+ 41667
|
0.6 USD |
|
9 years ago
Jul 22, 2015
|
Bought
29.2 K USD
|
COOPER JOHN G
President & CEO
|
+ 41667
|
0.7 USD |
|
11 years ago
Feb 19, 2013
|
Bought
8.64 K USD
|
Leone John R
Director
|
+ 3000
|
2.88 USD |
|
14 years ago
Dec 17, 2010
|
Sell 148
USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
- 700
|
0.2121 USD |
|
14 years ago
Dec 17, 2010
|
Sell 3.45 K
USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
- 16300
|
0.2116 USD |
|
16 years ago
Nov 20, 2008
|
Bought
13.1 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 14674
|
0.895 USD |
|
16 years ago
Nov 19, 2008
|
Bought
8.98 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 9655
|
0.93 USD |
|
16 years ago
Nov 18, 2008
|
Bought
25.7 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 25671
|
1 USD |
|
16 years ago
Nov 20, 2008
|
Bought
453 USD
|
ROSENTHALE MARVIN E
Director
|
+ 500
|
0.906 USD |
|
16 years ago
Nov 19, 2008
|
Bought
21.8 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 23400
|
0.93 USD |
|
16 years ago
Nov 18, 2008
|
Bought
1.1 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 1100
|
1 USD |
|
16 years ago
Nov 13, 2008
|
Bought
5.15 K USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
+ 5000
|
1.03 USD |
|
16 years ago
Nov 17, 2008
|
Bought
10.4 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 10000
|
1.045 USD |
|
16 years ago
Nov 17, 2008
|
Bought
40.4 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 40000
|
1.01 USD |
|
16 years ago
Nov 14, 2008
|
Bought
11.2 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 10000
|
1.12 USD |
|
16 years ago
Nov 13, 2008
|
Bought
4.39 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 4300
|
1.02 USD |
|
16 years ago
Nov 13, 2008
|
Bought
5.76 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 5700
|
1.01 USD |
|
16 years ago
Nov 11, 2008
|
Bought
6.6 K USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
+ 5000
|
1.32 USD |
|
16 years ago
Oct 17, 2008
|
Bought
19.8 K USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
+ 12000
|
1.65 USD |
|
16 years ago
Oct 08, 2008
|
Bought
0 USD
|
ROSENTHALE MARVIN E
Director
|
+ 0
|
0 USD |
|
16 years ago
Oct 08, 2008
|
Bought
16 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 10000
|
1.6 USD |
|
16 years ago
Oct 03, 2008
|
Bought
91.8 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 51289
|
1.79 USD |
|
16 years ago
Oct 03, 2008
|
Bought
0 USD
|
ROSENTHALE MARVIN E
Director
|
+ 0
|
0 USD |
|
16 years ago
Oct 01, 2008
|
Bought
18.9 K USD
|
Katzer Charles F
SVP, Manufacturing Operations
|
+ 10000
|
1.89 USD |
|
16 years ago
Sep 30, 2008
|
Bought
141 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 75000
|
1.8742 USD |
|
16 years ago
Sep 29, 2008
|
Bought
0 USD
|
ROSENTHALE MARVIN E
Director
|
+ 0
|
0 USD |
|
16 years ago
Sep 29, 2008
|
Bought
28 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 15000
|
1.87 USD |
|
16 years ago
Aug 18, 2008
|
Bought
19.3 K USD
|
Amick W Thomas
Director
|
+ 10000
|
1.93 USD |
|
16 years ago
Jun 04, 2008
|
Bought
18.4 K USD
|
Amick W Thomas
Director
|
+ 10000
|
1.84 USD |
|
16 years ago
May 12, 2008
|
Bought
0 USD
|
ROSENTHALE MARVIN E
Director
|
+ 0
|
0 USD |
|
16 years ago
May 12, 2008
|
Bought
18 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 10000
|
1.7999 USD |
|
17 years ago
Nov 19, 2007
|
Bought
972 USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
+ 400
|
2.43 USD |
|
17 years ago
Nov 19, 2007
|
Bought
8.71 K USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
+ 3600
|
2.42 USD |
|
17 years ago
Nov 19, 2007
|
Bought
9.56 K USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
+ 3900
|
2.45 USD |
|
17 years ago
Nov 20, 2007
|
Bought
36 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 15000
|
2.4 USD |
|
17 years ago
Nov 16, 2007
|
Bought
127 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 50000
|
2.54 USD |
|
17 years ago
Nov 15, 2007
|
Bought
23.2 K USD
|
Amick W Thomas
Director
|
+ 10000
|
2.32 USD |
|
17 years ago
Aug 03, 2007
|
Bought
53.6 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 25000
|
2.1452 USD |
|
17 years ago
Mar 14, 2007
|
Bought
20.8 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 10000
|
2.08 USD |
|
17 years ago
Mar 13, 2007
|
Bought
20.5 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 10000
|
2.05 USD |
|
17 years ago
Mar 15, 2007
|
Bought
9.41 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 4611
|
2.04 USD |
|
17 years ago
Mar 19, 2007
|
Bought
1.02 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 500
|
2.04 USD |
|
17 years ago
Mar 14, 2007
|
Bought
12.3 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 6000
|
2.05 USD |
|
17 years ago
Mar 14, 2007
|
Bought
20.8 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 10000
|
2.08 USD |
|
17 years ago
Mar 13, 2007
|
Bought
20.5 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 10000
|
2.05 USD |
|
17 years ago
Mar 09, 2007
|
Bought
83.8 K USD
|
LINK MAX
Director
|
+ 40000
|
2.0942 USD |
|
17 years ago
Mar 09, 2007
|
Bought
21.2 K USD
|
Amick W Thomas
Director
|
+ 10000
|
2.117 USD |
|
17 years ago
Mar 05, 2007
|
Bought
10.7 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 5500
|
1.951 USD |
|
17 years ago
Mar 06, 2007
|
Bought
20.3 K USD
|
LOPEZ DAVID L
Executive VP & Legal Counsel
|
+ 10000
|
2.0299 USD |
|
17 years ago
Mar 05, 2007
|
Bought
19.8 K USD
|
Katzer Charles F
SVP, Manufacturing Operations
|
+ 10000
|
1.985 USD |
|
17 years ago
Mar 02, 2007
|
Bought
37.6 K USD
|
COOPER JOHN G
EXEC. VP, CFO
|
+ 18000
|
2.0907 USD |
|
17 years ago
Mar 02, 2007
|
Bought
10.2 K USD
|
Miller Thomas F
SVP, Commercial..& Corp. Dev.
|
+ 5000
|
2.0366 USD |
|
17 years ago
Mar 02, 2007
|
Bought
10.7 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 5200
|
2.052 USD |
|
17 years ago
Mar 02, 2007
|
Bought
10.4 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 5000
|
2.082 USD |
|
17 years ago
Mar 01, 2007
|
Bought
9.92 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 4800
|
2.066 USD |
|
17 years ago
Mar 02, 2007
|
Bought
52.3 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 25000
|
2.0936 USD |
|
19 years ago
Oct 26, 2005
|
Bought
4.47 M USD
|
ESTEVE ANTONIO PHD
Director
|
+ 650000
|
6.88 USD |
|
19 years ago
Jun 03, 2005
|
Sell 102 K
USD
|
SEGAL ROBERT-MD
SVP, Chief Medical Officer
|
- 15000
|
6.8168 USD |
|
19 years ago
May 26, 2005
|
Sell 49.6 K
USD
|
NIVEN RALPH
SVP-Preclinical Dev- Former
|
- 7000
|
7.08 USD |
|
19 years ago
May 24, 2005
|
Sell 1.46 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 217
|
6.7079 USD |
|
19 years ago
May 24, 2005
|
Sell 6.69 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.6942 USD |
|
19 years ago
May 24, 2005
|
Sell 6.68 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.678 USD |
|
19 years ago
May 24, 2005
|
Sell 6.68 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.675 USD |
|
19 years ago
May 25, 2005
|
Sell 6.74 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.745 USD |
|
19 years ago
May 24, 2005
|
Sell 6.63 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.63 USD |
|
19 years ago
May 25, 2005
|
Sell 6.74 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.745 USD |
|
19 years ago
May 24, 2005
|
Sell 6.57 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.5738 USD |
|
19 years ago
May 25, 2005
|
Sell 6.74 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.7369 USD |
|
19 years ago
May 24, 2005
|
Sell 6.57 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.571 USD |
|
19 years ago
May 25, 2005
|
Sell 6.76 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.7624 USD |
|
19 years ago
May 25, 2005
|
Sell 6.77 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.766 USD |
|
19 years ago
May 24, 2005
|
Sell 6.56 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.563 USD |
|
19 years ago
May 25, 2005
|
Sell 6.76 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.764 USD |
|
19 years ago
May 24, 2005
|
Sell 6.56 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.562 USD |
|
19 years ago
May 24, 2005
|
Sell 6.55 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.554 USD |
|
19 years ago
May 25, 2005
|
Sell 6.77 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.774 USD |
|
19 years ago
May 25, 2005
|
Sell 6.8 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.802 USD |
|
19 years ago
May 25, 2005
|
Sell 6.84 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.836 USD |
|
19 years ago
May 24, 2005
|
Sell 19.6 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 3000
|
6.55 USD |
|
19 years ago
May 25, 2005
|
Sell 6.85 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev-Former
|
- 1000
|
6.846 USD |
|
19 years ago
May 23, 2005
|
Sell 36.6 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev- Former
|
- 5500
|
6.6561 USD |
|
19 years ago
May 23, 2005
|
Sell 1.88 K
USD
|
NIVEN RALPH
SVP- Preclinical Dev- Former
|
- 283
|
6.65 USD |
|
19 years ago
May 11, 2005
|
Sell 28.5 K
USD
|
NIVEN RALPH
Sr.VP PreClinical Dev - former
|
- 4450
|
6.4 USD |
|
19 years ago
May 11, 2005
|
Sell 7.72 K
USD
|
NIVEN RALPH
Sr.VP PreClinical Dev - former
|
- 1200
|
6.43 USD |
|
19 years ago
May 11, 2005
|
Sell 3.86 K
USD
|
NIVEN RALPH
Sr.VP PreClinical Dev - former
|
- 600
|
6.44 USD |
|
19 years ago
Apr 29, 2005
|
Bought
1.13 K USD
|
ESTEVE ANTONIO PHD
Director
|
+ 200
|
5.6482 USD |
|
19 years ago
Apr 29, 2005
|
Bought
1.84 K USD
|
ESTEVE ANTONIO PHD
Director
|
+ 325
|
5.65 USD |
|
19 years ago
Mar 24, 2005
|
Bought
35.7 K USD
|
COOPER JOHN G
Exec. VP, CFO
|
+ 6000
|
5.9423 USD |
|
19 years ago
Mar 21, 2005
|
Bought
34.1 K USD
|
LOPEZ DAVID L
Senior VP & Legal Counsel
|
+ 6000
|
5.684 USD |
|
19 years ago
Mar 17, 2005
|
Bought
78.5 K USD
|
SCHABER CHRISTOPHER
Exec. V.P. & Chief Operating
|
+ 15000
|
5.2341 USD |
|
19 years ago
Mar 16, 2005
|
Bought
185 K USD
|
CAPETOLA ROBERT J
President/CEO
|
+ 35000
|
5.2993 USD |
|
20 years ago
Dec 10, 2004
|
Sell 82.8 K
USD
|
NIVEN RALPH
Sr. VP Preclinical Development
|
- 10000
|
8.28 USD |
|
20 years ago
Dec 03, 2004
|
Bought
3.46 M USD
|
ESTEVE ANTONIO PHD
Director
|
+ 500000
|
6.93 USD |
|
20 years ago
May 28, 2004
|
Sell 53.8 K
USD
|
COOPER JOHN G
Exec. VP, CFO
|
- 5000
|
10.75 USD |
|
20 years ago
May 28, 2004
|
Sell 54 K
USD
|
COOPER JOHN G
Exec. VP, CFO
|
- 5000
|
10.8 USD |
|
20 years ago
May 28, 2004
|
Sell 108 K
USD
|
LOPEZ DAVID L
Senior VP & Legal Counsel
|
- 10000
|
10.8429 USD |
|
20 years ago
May 27, 2004
|
Sell 210 K
USD
|
COOPER JOHN G
Executive VP and CFO
|
- 20000
|
10.5089 USD |
|
20 years ago
Apr 30, 2004
|
Bought
20 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 1800
|
11.1 USD |
|
20 years ago
Apr 26, 2004
|
Sell 307 K
USD
|
ZODDA DENI M PHD
Senior V.P., Business Dev.
|
- 24000
|
12.805 USD |
|
20 years ago
Apr 15, 2004
|
Bought
66.8 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 5500
|
12.15 USD |
|
20 years ago
Apr 05, 2004
|
Sell 189 K
USD
|
DAVIS CYNTHIA
V.P., Controller
|
- 15000
|
12.607 USD |
|
20 years ago
Apr 08, 2004
|
Sell 189 K
USD
|
DAVIS CYNTHIA
V.P., Controller
|
- 15000
|
12.607 USD |
|
20 years ago
Apr 06, 2004
|
Sell 249 K
USD
|
MCDADE HERBERT H
Director
|
- 20000
|
12.43 USD |
|
20 years ago
Apr 05, 2004
|
Bought
38.2 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 3000
|
12.75 USD |
|
20 years ago
Mar 22, 2004
|
Bought
13.4 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 1200
|
11.15 USD |
|
20 years ago
Mar 22, 2004
|
Bought
14.5 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 1300
|
11.18 USD |
|
20 years ago
Mar 22, 2004
|
Bought
45 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 4000
|
11.25 USD |
|
20 years ago
Mar 19, 2004
|
Bought
13.8 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 1200
|
11.48 USD |
|
20 years ago
Mar 19, 2004
|
Bought
30 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 2500
|
12.01 USD |
|
20 years ago
Mar 19, 2004
|
Bought
34.6 K USD
|
ROSENTHALE MARVIN E
Director
|
+ 3000
|
11.52 USD |
|
20 years ago
Mar 15, 2004
|
Bought
3.13 K USD
|
ESTEVE ANTONIO PHD
Director
|
+ 240
|
13.04 USD |
|
21 years ago
Oct 17, 2003
|
Bought
8.62 K USD
|
ESTEVE ANTONIO PHD
Director
|
+ 1150
|
7.5 USD |
|
21 years ago
Aug 14, 2003
|
Sell 101 K
USD
|
MCDADE HERBERT H
Director
|
- 13900
|
7.29 USD |
|
21 years ago
Aug 14, 2003
|
Sell 73.7 K
USD
|
MCDADE HERBERT H
Director
|
- 10100
|
7.3 USD |
|
21 years ago
Aug 14, 2003
|
Sell 1.46 K
USD
|
MCDADE HERBERT H
Director
|
- 200
|
7.31 USD |
|
21 years ago
Aug 14, 2003
|
Sell 5.86 K
USD
|
MCDADE HERBERT H
Director
|
- 800
|
7.32 USD |
|
21 years ago
Aug 14, 2003
|
Sell 7.34 K
USD
|
MCDADE HERBERT H
Director
|
- 1000
|
7.34 USD |
|
21 years ago
Aug 14, 2003
|
Sell 26.5 K
USD
|
MCDADE HERBERT H
Director
|
- 3600
|
7.35 USD |
|
21 years ago
Aug 14, 2003
|
Sell 1.47 K
USD
|
MCDADE HERBERT H
Director
|
- 200
|
7.36 USD |
|
21 years ago
Aug 14, 2003
|
Sell 738
USD
|
MCDADE HERBERT H
Director
|
- 100
|
7.38 USD |
|
21 years ago
Aug 14, 2003
|
Sell 741
USD
|
MCDADE HERBERT H
Director
|
- 100
|
7.41 USD |
|
21 years ago
Aug 15, 2003
|
Sell 26.2 K
USD
|
MCDADE HERBERT H
Director
|
- 3621
|
7.24 USD |
|
21 years ago
Aug 13, 2003
|
Bought
14.5 K USD
|
CAPETOLA ROBERT J
Presdient and CEO
|
+ 2000
|
7.24 USD |
7. News
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.”
globenewswire.com
- 1 month ago
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has engaged New Growth Advisors (“NGA”), a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transactions, as its strategic advisor to lead a process in respect of Windtree's cardiovascular portfolio, including a potential out-licensing transaction or asset sale. NGA has advised on transactions with an aggregate value approaching $400 million from 2023 through 2024.
globenewswire.com
- 1 month ago
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates.
globenewswire.com
- 1 month ago
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company has completed national phase filings of patent applications around the world, including in the United States, Germany, France, Italy, Japan and China.
globenewswire.com
- 2 months ago
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
globenewswire.com
- 3 months ago
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
globenewswire.com
- 3 months ago
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term milestones WARRINGTON, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it will hold a virtual Investor Day Presentation on October 1 at 3pm ET.
globenewswire.com
- 3 months ago
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments
globenewswire.com
- 3 months ago
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024 and provided key business updates.
globenewswire.com
- 4 months ago
Windtree Announces New Additions and Changes to Its Board of Directors
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced changes to its board of directors, effective August 13, 2024, which include the appointment of Saundra Pelletier and Jed Latkin as two new independent directors with significant public company director and executive leadership.
globenewswire.com
- 5 months ago
Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?
Windtree Therapeutics (NASDAQ: WINT ) stock is rocketing higher on Friday after the biotechnology company provided an update on its clinical trial of istaroxime. Windtree Therapeutics notes that it is expecting its Phase 2 Phase 2 SEISMiC Extension Study to complete enrollment within the company weeks.
investorplace.com
- 5 months ago
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data
globenewswire.com
- 5 months ago
8. Profile
Summary
Windtree Therapeutics, Inc. WINT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.42 M
Dividend Yield
16.37%
Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Contact
2600 Kelly Road, Warrington, PA, 18976-3622
https://windtreetx.com
IPO
Date
Aug. 7, 1995
Employees
20
Officers
Ms. Jamie McAndrew
Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Controller & Corporate Secretary
Dr. Pratap Paruchuru
Executive Director of Clinical Development
Ms. Tracy Rarick
Head of Operations & Program Management
Dr. Steven G. Simonson M.D., M.H.S
Senior Vice President & Chief Medical Officer
Mr. Craig E. Fraser
President, Chief Executive Officer & Chairman
Mr. Eric L. Curtis M.B.A.
Senior Vice President & Chief Operating Officer
Mr. George Cox
Vice President of Technical Operations